Northerner
Admin (Retired)
- Relationship to Diabetes
- Type 1
Zosano Pharma Inc. is taking the shot out of the needle.
The Fremont company struck a deal this week to turn Danish pharmaceutical giant Novo Nordisk's experimental injectable type 2 diabetes drug into a patient-friendly patch. The deal could bring privately held Zosano upwards of $60 million in milestone payments, on top of undisclosed upfront cash, and another $55 million for follow-on programs.
http://www.bizjournals.com/sanfrancisco/blog/biotech/2014/02/zosano-novo-nordisk-diabetes-patch.html
The Fremont company struck a deal this week to turn Danish pharmaceutical giant Novo Nordisk's experimental injectable type 2 diabetes drug into a patient-friendly patch. The deal could bring privately held Zosano upwards of $60 million in milestone payments, on top of undisclosed upfront cash, and another $55 million for follow-on programs.
http://www.bizjournals.com/sanfrancisco/blog/biotech/2014/02/zosano-novo-nordisk-diabetes-patch.html